CYP3A5*3 genotypes and advanced non-small cell lung cancer development No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ASCO Annual Meeting. This ...
Please provide your email address to receive an email when new articles are posted on . “The challenge of modern cancer therapy is still to cure but also to prevent late effects, especially in ...
Childhood cancer survivors (CCS) are at risk of developing subsequent malignant neoplasms (SMNs) resulting from exposure to prior therapies. CCS with underlying cancer predisposition syndromes are at ...
Five vitamin D receptor polymorphisms (FokI, BsmI, Apa1, Taq1, and Cdx2) and lung cancer risk. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include a ...
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results